QUESTIONS ABOUT COVID-19 AND THE VACCINE? GET ANSWERS HERE
These are extraordinary times—we’re here to help
At Novartis, we are committed to the health and well-being of our patients, and we are closely monitoring the novel coronavirus (COVID-19) situation. Here are answers to some of the most frequently asked questions.
It's important that you take precautions to reduce the risk of contracting COVID-19 and contact your prescribing healthcare provider if you have any questions or concerns about your COSENTYX® (secukinumab) treatment.
You can also reach out to 1-844-COSENTYX (1-844-267-3689), or call a COSENTYX® Connect Team Member from COSENTYX® Connect.
To learn more about how Novartis is responding to COVID-19, visit novartis.com/coronavirus.
Can COVID-19, or the COVID-19 vaccine, affect my treatment with COSENTYX?
Paying for and getting COSENTYX
Visiting my doctor
Novartis response to COVID-19
Novartis committed to donating up to USD 40 million to support communities around the world impacted by the pandemic. This included the Novartis COVID-19 Response Fund and a US COVID- 19 Community Response Fund, established by Novartis and the Novartis US Foundation, that provided cash and in-kind donations for immediate response and recovery efforts related to the pandemic in the US.
To learn more about how Novartis is responding to COVID-19, visit novartis.com/coronavirus.
Where can I find additional resources?
To follow the latest information on COVID-19, visit the Centers for Disease Control (CDC) ↗ or the World Health Organization (WHO) ↗.
Click on the advocacy organization's logo below for the latest news about your condition and COVID-19.
National Psoriasis Foundation, Arthritis Foundation, Spondylitis Association of America names and logos are trademarks of their respective owners, used with permission. Novartis does not endorse and is not responsible for content of these third-party sites.
*Program Terms & Conditions: Limitations apply. Valid only for those with private insurance. Program provides up to $16,000 annually for the cost of COSENTYX and up to $150 per infusion (up to $1,950 annually) for the cost of administration. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts. Patient is responsible for any costs once limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state healthcare program, (ii) where patient is not using insurance coverage at all, (iii) where the patient’s insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient’s insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Program is not valid where prohibited by law. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or healthcare savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the US and Puerto Rico. This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.
†The Covered Until You're Covered Program is available for COSENTYX subcutaneous injection only. Eligible patients must have private insurance, a valid prescription for COSENTYX, and a denial of insurance coverage based on a prior authorization request. Program requires the submission of an appeal of the coverage denial within the first 90 days of enrollment in order to remain eligible. Program provides COSENTYX for free to eligible patients for up to two years, or until they receive insurance coverage approval, whichever occurs earlier. A valid prescription consistent with FDA-approved labeling is required. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Patients may be asked to reverify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. Enrolled patients awaiting coverage for COSENTYX after two years may be eligible for a limited Program extension. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this Program without notice.